New Low-Dose tdap vaccine trial aims to boost protection with fewer side effects
NCT ID NCT07418372
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new version of the Tdap vaccine (which protects against tetanus, diphtheria, and whooping cough) that has reduced antigens. The goal is to see if it is safe and triggers a strong immune response in people aged 6 and up. Around 660 volunteers will receive either the low-dose or high-dose experimental vaccine, or a standard vaccine for comparison. Researchers will monitor for side effects and measure antibody levels 30 days after vaccination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Reduced-antigen tetanus, diphtheria, and acellular pertussis vaccine
What this could lead to
If successful, this could provide a safer booster option for older children and adults to protect against tetanus, diphtheria, and whooping cough.
What could go wrong
This is an early-phase trial (I/II) with only 660 participants, so results may not confirm broad effectiveness or safety. Side effects like injection-site reactions or fever are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangjin District Center for Disease Control and Prevention
Chongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••